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Received April 11, 2016; accepted June 30, 2016AbstractBackground: Platelet count (PC) and fatty liver are both associated with metabolic syndrome (MS), obesity, and type 2 diabetes. While PC
increases in obesity and type 2 diabetes, the severity of hepatic fibrosis caused by fatty liver reduces PC. We aimed to investigate the correlation
of PC and MS in patients with and without fatty liver.
Methods: We enrolled consecutive patients who received health check-ups at Taipei Veterans General Hospital from 2002 to 2009. Ultraso-
nography was used to diagnose fatty liver, and MS was diagnosed according to the criteria defined by the International Diabetes Federation Task
Force on Epidemiology and Prevention.
Results: Among the 29,797 patients, MS was present in 28.74%. Higher PC was correlated with MS using multivariate analysis, while fatty liver
had the strongest association with MS. After dividing the patients by the presence or absence of fatty liver, higher PC was still associated with
MS in both groups. The patients were further stratified by age and gender, and MS was correlated with PC among all age groups in women and in
men under 60 years of age; however, the association between PC and MS did not reach statistical difference in men older than 60 years.
Conclusion: There is a significant correlation between PC and MS, and the correlation exists independent of gender, age, and fatty liver. PC may
act as a surrogate marker for MS, and physicians should be concerned with the presence of MS among patients with high PC.
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Metabolic syndrome (MS) has several risk factors,
including central obesity, dyslipidemia, raised blood pressure,
and fasting glucose for cardiovascular disease and Type 2
diabetes mellitus.1,2 Fatty liver disease used to be considered
an incidental pathological finding in Type 2 diabetes andiated with metabolic syndrome independent of fatty liver diagnosis, Journal of
.003
sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
PaƟents receiving 
health check-up (n 
= 34,346)
PaƟents included
(n = 29,797)
With metabolic 
syndrome (n = 
8564)
Without metabolic 
syndrome (n = 
21,233)
Excluding
HBsAg(+)/anƟ-HCV(+) (n = 
88)
HBsAg(-)/anƟ-HCV(+) (n = 
819)
HBsAg(+)/anƟ-HCV(-) (n = 
3642)
2 K.-C. Fang et al. / Journal of the Chinese Medical Association xx (2016) 1e8
+ MODELobesity; however, it is found to be strongly related with fea-
tures of MS and even considered to be included in the defi-
nition of MS.3,4
Higher PC is associated with cardiovascular disease and
vascular complications as a result of its role in inflammation
and thrombosis; also, platelet activation is observed in people
with diabetes, hypertriglyceridemia, and insulin resistance.5e9
Diabetes, hypertriglyceridemia, and insulin resistance are
strongly associated with MS, and previous studies have found
that PC is also elevated in patients with MS after adjustment
for age, gender, ethnicity, and total cholesterol.10,11 On the
contrary, decreased PC is observed when significant hepatic
fibrosis develops in patients with fatty liver, especially in
conditions of nonalcoholic steatohepatitis, which is another
disease that is highly associated with MS.12,13
Although MS, PC, and fatty liver are closely related, the
association between PC among patients with MS with or
without fatty liver has not been clarified by comprehensive
analyses. The present study therefore aimed to investigate the
correlation of PC and MS in patients with and without fatty
liver from a large-scale cohort in Taiwan.
2. Methods2.1. Study populationWith faƩy liver (n = 
6295)
Without faƩy liver 
(n = 2269)
With faƩy liver  (n 
= 6960)
Without faƩy liver 
(n = 14,273)
Fig. 1. Flow chart of patients in the study.From the years 2002 to 2009, a total of 34,346 consecutive
patients received health check-ups in the Healthcare Center at
the Taipei Veterans General Hospital.14e16 After excluding
patients with hepatitis B virus (HBV) infection, hepatitis C
virus (HCV) infection, and HBV/HCV dual infections, 29,797
patients were enrolled for the final analysis (Fig. 1). All of
them received complete clinical evaluations, laboratory ex-
aminations, and abdominal sonography. Body mass index
(BMI) was defined as body weight in kilograms divided by the
square of body height in meters.
Three of the following five abnormal findings are required for
a diagnosis ofMS according to the joint interim statement of the
International Diabetes Federation Task Force on Epidemiology
and Prevention1: elevated waist circumference (WC, men
90 cm or women 80 cm), triglyceride (TG) 150 mg/dL,
low high-density lipoprotein (HDL)echolesterol (men<40mg/
dL or women <50 mg/dL), systolic blood pressure (BP)
130 mm Hg and/or diastolic BP 85 mm Hg, and fasting
glucose 100 mg/dL. Ultrasonography was performed to di-
agnose fatty liver according to the practice guideline proposed
by the American Gastroenterological Association.17
This study followed the standards of the Declaration of
Helsinki and was approved by the Institutional Review Board of
Taipei Veterans General Hospital. As the dataset used in this
study consisted of de-identified data from a retrospective cohort,
the requirement for written informed consent was waived.2.2. Biochemical, hematology, and serological markersVenous blood samples were collected after an overnight
fast. Serum HBV surface antigen (HBsAg) was tested by aPlease cite this article in press as: Fang K-C, et al., Higher platelet counts are assoc
the Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.07radioimmunoassay (Abbott Laboratories, North Chicago, IL,
USA), and antibodies to HCV were tested using a second-
generation enzyme immunoassay (Abbott Laboratories).
Serum biochemistry were measured with a Roche/Hitachi
Modular Analytics System (Roche Diagnostics GmbH, Man-
nheim, Germany). Hematological analysis was performed
using a Beckman Coulter LH 780 Hematology Blood
Analyzer (Beckman Coulter, Miami, FL, USA).2.3. Statistical analysisThe study cohort was first stratified by gender, and patients
with fatty liver were selected for further analysis. PC was
stratified by age to show association with MS in both men and
women. Pearson c2 and Student t test analyses were per-
formed to compare categorical and continuous variables with
two samples, respectively. Variables with statistical signifi-
cance ( p < 0.05) or approximate significance ( p < 0.1) in
univariate analysis were further included in multivariate
analysis using a logistic regression model with the forward
stepwise selection procedure. A p value < 0.05 was considerediated with metabolic syndrome independent of fatty liver diagnosis, Journal of
.003
Table 1
Factors associated with male patients with and without metabolic syndrome.
All
(N ¼ 16,098)
Metabolic syndrome
(n ¼ 6525)
Nonmetabolic syndrome
(n ¼ 9573)
p
BMI, kg/m2 a 24.64 ± 3.38 26.1 ± 3.12 23.64 ± 3.19 <0.001
Age, (y) a 53.0 ± 13.7 55.1 ± 12.6 51.5 ± 14.2 <0.001
WC, cm a 87.5 ± 9.2 91.8 ± 8.1 84.5 ± 8.7 <0.001
SBP, mm Hg a 126.8 ± 17.1 133.6 ± 16.7 122.1 ± 15.9 <0.001
DBP, mm Hg a 79.6 ± 14.4 83.8 ± 16.3 76.6 ± 12.1 <0.001
Fasting glucose, mg/dL a 97.6 ± 26.8 108.9 ± 35.4 90.0 ± 14.6 <0.001
Cholesterol, mg/dL a 198.1 ± 36.3 201.2 ± 37.3 196.0 ± 35.4 <0.001
HDL, mg/dL a 47.9 ± 12.1 41.6 ± 9.7 52.2 ± 11.7 <0.001
LDL, mg/dL a 126.9 ± 32.2 128.0 ± 32.8 126.2 ± 31.7 0.001
TG, mg/dL a 150.1 ± 98.6 205.7 ± 117.6 112.2 ± 58.3 <0.001
AST, U/L a 24.1 ± 13.3 25.9 ± 17.3 22.8 ± 9.4 <0.001
ALT, U/L a 30.9 ± 24.2 36.1 ± 29.9 27.3 ± 18.6 <0.001
GGT, U/L a 29.8 ± 43.2 36.3 ± 55.4 25.4 ± 31.6 <0.001
Platelets, 1000/mm3 a 241.1 ± 57.5 242.9 ± 59.9 239.9 ± 55.8 0.001
Fatty liver (Yes/no)
(%)
8710/7388
(54.1/45.9)
4760/1765
(73.0/27.0)
3950/5623
(41.3/58.7)
<0.001
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body mass index; DBP ¼ diastolic blood pressure; GGT ¼ g-glutamyltransferase;
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; SBP ¼ systolic blood pressure; TG ¼ triglyceride; WC ¼ waist circumference.
a Data expressed as mean ± standard deviation.
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performed with SPSS for Windows version 17.0 (SPSS, Chi-
cago, IL, USA).
3. Results3.1. Patient characteristics stratified by gender and MSThe demographic data of male patients are summarized in
Table 1. The mean age of the male population was 53.0 years,
and 6525 (40.53%) had MS. Male patients with MS were older
and had higher BMIs, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), g-glutamyltranspeptidase
(GGT), fatty liver prevalence, and PC.Table 2
Factors associated with female patients with and without metabolic syndrome.
All
(N ¼ 13,699)
Metaboli
(n ¼ 203
BMI, kg/m2 a 22.85 ± 3.57 26.65 ±
Age, (y) a 51.3 ± 12.6 60.0 ± 1
WC, cm a 79.5 ± 9.8 90.5 ± 9
SBP, mm Hg a 121.3 ± 19.8 138.9 ±
DBP, mm Hg a 75.2 ± 13.7 83.4 ± 2
Fasting glucose, mg/dL a 93.0 ± 21.9 115.3 ±
Cholesterol, mg/dL a 200.5 ± 37.8 209.0 ±
HDL, mg/dL a 60.5 ± 15.2 47.1 ± 1
LDL, mg/dL a 123.4 ± 33.6 132.2 ±
TG, mg/dL a 107.3 ± 66.8 187.4 ±
AST, U/L a 21.8 ± 13.0 26.4 ± 2
ALT, U/L a 22.5 ± 18.5 31.8 ± 2
GGT, U/L a 18.8 ± 26.3 27.5 ± 3
Platelet, 1000/mm3 a 260.1 ± 62.0 262.2 ±
Fatty liver (yes/no)
(%)
4545/9154
(33.2/66.8)
1535/504
(75.3/24.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; SBP ¼ systolic
a Data expressed as mean ± standard deviation.
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the Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.07The demographic data of female patients are summarized in
Table 2. The mean age of the female population was
51.3 years, and 2039 (14.88%) had MS. Similarly, female
patients with MS were older and had higher BMI, ALT, AST,
GGT, and PC. They also had a significantly higher rate of fatty
liver compared with those without MS (75.3% vs. 25.8%,
p < 0.001).3.2. Factors associated with MS by multivariate analysisUsing multivariate analysis, the presence of fatty liver
diagnosed by ultrasonography had the strongest association
with MS in both men and women, with odds ratios of 2.205
(95% confidence interval 2.0e2.4) and 3.275 (95% confidencec syndrome
9)
Nonmetabolic syndrome
(n ¼ 11,660)
p
3.84 22.19 ± 3.07 <0.001
1.1 49.8 ± 12.3 <0.001
.3 77.5 ± 8.5 <0.001
18.4 118.2 ± 18.4 <0.001
0.9 73.7 ± 11.4 <0.001
34.4 89.2 ± 15.9 <0.001
39.9 199.0 ± 37.2 <0.001
0.2 62.8 ± 14.8 <0.001
34.7 121.9 ± 33.1 <0.001
88.0 93.3 ± 50.7 <0.001
0.6 21.0 ± 10.9 <0.001
6.0 20.9 ± 16.3 <0.001
1.9 17.3 ± 24.9 <0.001
66.2 259.7 ± 61.2 0.009
7)
3010/8650
(25.8/74.2)
<0.001
mass index; DBP ¼ diastolic blood pressure; GGT ¼ g-glutamyltransferase;
blood pressure; TG ¼ triglyceride; WC ¼ waist circumference.
iated with metabolic syndrome independent of fatty liver diagnosis, Journal of
.003
Table 3
Factors associated with metabolic syndrome by multivariate analysis.
Odds ratio 95% confidence level p
All patients
Female
BMI, per kg/m2 1.311 1.288e1.335 <0.001
Age, per year 1.065 1.059e1.071 <0.001
ALT, per U/L 1.007 1.004e1.009 <0.001
GGT, per U/L 1.004 1.002e1.005 <0.001
Platelets, per 1000/mm3 1.001 1.001e1.002 0.002
Fatty liver 3.275 2.888e3.714 <0.001
Male
BMI, per kg/m2 1.242 1.225e1.259 <0.001
Age, per year 1.032 1.029e1.035 <0.001
ALT, per U/L 1.006 1.004e1.008 <0.001
GGT, per U/L 1.005 1.004e1.007 <0.001
Platelets, per 1000/mm3 1.002 1.001e1.002 <0.001
Fatty liver 2.205 2.040e2.384 <0.001
Patients with fatty liver
Female
BMI, per kg/m2 1.382 1.339e1.426 <0.001
Age, per year 1.080 1.070e1.089 <0.001
ALT, per U/L 1.010 1.005e1.015 <0.001
Platelets, per 1000/mm3 1.002 1.000e1.003 0.028
Male
BMI, per kg/m2 1.351 1.320e1.383 <0.001
Age, per year 1.032 1.028e1.037 <0.001
ALT, per U/L 1.005 1.001e1.009 0.021
GGT, per U/L 1.005 1.003e1.007 <0.001
Platelets, per 1000/mm3 1.002 1.001e1.003 0.002
Patients without fatty liver
Female
BMI, per kg/m2 1.270 1.242e1.297 <0.001
Age, per year 1.054 1.046e1.061 <0.001
ALT, per U/L 1.006 1.003e1.009 <0.001
GGT, per U/L 1.005 1.002e1.007 0.001
Platelets, per 1000/mm3 1.001 1.000e1.002 0.027
Male
BMI, per kg/m2 1.185 1.166e1.205 <0.001
Age, per year 1.031 1.027e1.036 <0.001
ALT, per U/L 1.007 1.005e1.009 <0.001
GGT, per U/L 1.005 1.004e1.007 <0.001
Platelets, per 1000/mm3 1.002 1.001e1.003 <0.001
ALT ¼ alanine aminotransferase; BMI ¼ body mass index; GGT ¼ g-
glutamyltransferase.
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ALT, and GGT were correlated as well (Table 3 and Fig. 2A).
Stratifying patients by age revealed that those with fatty liver
had a higher rate of MS in all age groups (Fig. 2B). Further
analysis disclosed that a higher serum ALT level was associ-
ated with MS in people with fatty liver disease and the asso-
ciation existed in all age groups as well (Fig. 2C and 2D).3.3. J curve phenomenon occurred between PC and MSThe prevalence of MS was further analyzed after the male
and female population was separated into 10 quantiles based
on PC from 1 (the lowest PC group) to 10 (the highest PC
group) (Fig. 3A and 3B). The result showed a J curve phe-
nomenon in both genders, and the phenomenon was more
prominent in men. The prevalence of fatty liver was also
evaluated after the male and female population was divided toPlease cite this article in press as: Fang K-C, et al., Higher platelet counts are assoc
the Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.0710 quantiles by PC (Fig. 3C and 3D). No J curve phenomenon
was noted between fatty liver disease and PC.3.4. PC was associated with MS irrespective of fatty
liver and ageAs fatty liver was the most important determinant of MS in
this study, we divided patients by fatty liver disease to further
assess the impact of PC on MS. As shown in Table 3, higher
PC was still an independent risk factor associated with MS in
both genders irrespective of the status of fatty liver.
The prevalence of MS in each age group among men and
women is documented in Table 4. With further analysis, higher
PC was correlated with MS among all age groups in women
and in men under 60 years of age (Fig. 4). The association
between PC and MS did not reach statistical significance in
men older than 60 years.
4. Discussion
Our large study demonstrated that PC was higher in MS
patients, and, more importantly, the association existed after
adjusting for age, gender, and the status of fatty liver.
The prevalence of MS is nearly 35% in the United States,
according to a recent analysis of the population from 2003 to
2012.18 While the prevalence of MS was approximately 12%
between 1999 and 2002 in Taiwan, it was much higher in the
current study (28%), which may have been because of west-
ernization of diet, greater awareness of the syndrome, or
higher socioeconomic status of the patients.19
Nonalcoholic fatty liver disease (NAFLD) is strongly
associated with MS, which is demonstrated by the fact that
approximately 90% of the patients with fatty liver have more
than one feature of MS, and 33% of them have three or more.
NAFLD has also been seen as the hepatic expression of MS.4
The association between NAFLD and MS exists in not only
obese and type 2 diabetes mellitus patients but also nonobese
and nondiabetic individuals.20 In concordance with previous
published results, our current study showed that the prevalence
of MS increased with age (Fig. 2B), and that fatty liver was the
strongest association factor with MS in both genders (Table 3).
Of note, people with fatty liver disease who had active hepatic
necroinflammation and elevated serum ALT levels were
correlated with an even higher rate of MS, and the association
existed among all age groups (Fig. 2C and 2D).
Regarding the pathogenic role of mean platelet volume
(MPV) and PC in the development of MS, growing evidence
suggests that MPV should be regarded as a new inflammation
marker and associated with the risk of cardiovascular disease,
Type 2 diabetes, and MS.21 Information with respect to MPV
might not have been available in the current study because the
data were obtained from routine health check-ups; however, a
recently published study demonstrated a close association
between MPV and PC.22 According to published literature,
more and larger reactive platelets develop in the presence of
conditions such as obesity and endothelial dysfunction under
the influence of growth factors and cytokines.23 Additionally,iated with metabolic syndrome independent of fatty liver diagnosis, Journal of
.003
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Fig. 2. Metabolic syndrome prevalence divided by (A) gender and fatty liver disease, (B) age and fatty liver disease, (C) gender and ALT among people with fatty
liver (D) age and ALT among people with fatty liver. ALT ¼ alanine aminotransferase.
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vascular complications because of their role in inflammation
and thrombosis. Stokes et al5e8 mentioned that platelets
deposited chemoattractants on the vessel wall and directly
interact with leukocytes and the vessel wall through the
mediation of factors, such as P-selectin, glycoprotein (GP)1a,
GPIIb/IIIa, and CD40L.5e8 Platelet activation has also been
observed in people with Type 2 diabetes, hyper-
triglyceridemia, and insulin resistance through the decreased
production of nitric oxide and increased oxidative stress.9 In-
sulin resistance, obesity, and high triglyceride are the under-
lying factors for MS, and previous studies have found that PC
is elevated in patients with MS after adjustment for age,
gender, ethnicity, and total cholesterol.10,11,24e26 The present
study confirmed that PC was significantly associated with MS
after adjustment for age, gender, and status of fatty liver (Table
3 and Fig. 4). Although other factors, such as age, BMI, and
fatty liver, had higher odds ratios than PC had, multivariate
analysis and stratified analysis confirmed that a higher PC was
correlated with MS. It indicated that platelet activation might
also play an important and independent role in MS. Further
prospective studies are warranted to validate this phenomenon.
Different from our study results, a Korean study that
enrolled 3827 patients showed that PC and MS were associ-
ated in women only.27 The possible explanations for thisPlease cite this article in press as: Fang K-C, et al., Higher platelet counts are assoc
the Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.07discrepancy were different population composition and a
larger sample size compared with our current study. Also, our
study showed that the association between PC and MS was
less significant for participants above 60 years of age, espe-
cially in men. Older patients of each ethnicity consistently
have lower PC than young adults, and the phenomenon may be
explained by a survival advantage to having lower PC or
diminished hematopoietic stem-cell reserve.28,29 Accordingly,
the linkage between PC and MS in elderly patients might be
weakened, but the hypothesis needs to be further elucidated.
The role of PC in patients with fatty liver is intriguing.
Obesity is characterized by chronic inflammation and associ-
ated with an increased risk of fatty liver, and insulin resistance
is a universal finding in the disease.30,31 Meanwhile, PC is
independently associated with insulin resistance, and the
decrease in PC observed in obesity patients after bariatric
surgery may reflect decreased hepatic inflammation.32,33 In
contrast, a linear decrease of PC with increasing histological
severity of hepatic fibrosis in fatty liver is noticed, especially
in conditions of nonalcoholic steatohepatitis. PC is included in
several noninvasive scores, which reveal a negative correlation
with fibrotic levels in patients with fatty liver diseases.12,13
While MS is related to PC and fatty liver, the relationship
between PC among patients with MS with or without fatty
liver was not clarified. Based on this study, we found that PCiated with metabolic syndrome independent of fatty liver diagnosis, Journal of
.003
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Fig. 3. Metabolic syndrome prevalence in different quantiles based on PC in (A) women and (B) men. Fatty liver prevalence in different quantiles by PC in (C)
women and (D) men. PC ¼ platelet count.
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and gender. After dividing patients by the status of fatty liver,
PC was still correlated with MS (Table 3).
Our study demonstrated a J curve phenomenon between PC
and MS, which is consistent with the concept that extreme
values of PC are related to cardiovascular diseases.34 However,
the phenomenon did not apply to the relationship between PC
and fatty liver. The exact mechanism is not fully elucidated.
However, previous studies showed that the grade of steatosis
might reduce with the progression of hepatic fibrosis and
reduced PC in patients with fatty liver disease.35 It may
explain the lower PC being paired with increased fibrosis and
reduced steatosis.
The strengths of this study were the large sample size and
detailed biochemical data, which provide robust evidence to
elucidate the correlation between PC and MS. However,
several limitations need to be addressed. First, our studyTable 4
Metabolic syndrome prevalence in different age groups.
Male
Age (y) <30 30e40
People with metabolic syndrome (%) 106 (15.6) 561 (28.9)
People without metabolic syndrome (%) 547 (84.4) 1382 (71.1)
Female
Age (y) <30 30e40
People with metabolic syndrome (%) 16 (2.3) 49 (2.8)
People without metabolic syndrome (%) 673 (97.7) 1719 (97.2)
Please cite this article in press as: Fang K-C, et al., Higher platelet counts are assoc
the Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.07population had a high socioeconomic status, and could afford
the expense of a physical check-up in a medical center.
Whether the results of this study could represent the general
population in Taiwan requires further studies to be validated.
Second, alcohol consumption was not recorded and assessed.
However, the prevalence of alcoholism was reported to be
1.5% in Taiwanese communities; therefore, it might have little
influence on the result.36 Third, PC can be influenced by other
factors, including infection, medication, and hematological
diseases. Given that the patients received physical check-ups
in the hospital, the incidence of acute infection should be
minimal. The incidence of drug-induced thrombocytopenia
was also low, at about one or two cases per 100,000 per year.
Primary hematological diseases account for <5% of patients
with elevated PC.37,38 These factors might have had only a
little impact on the current study. Fourth, whether patients had
diabetes mellitus, hypertension, or dyslipidemia was unknown40e50 50e60 60e70 70
1418 (39.5) 2265 (43.1) 1246 (48.7) 929 (45.0)
2175 (60.5) 2991 (56.9) 1314 (51.3) 1137 (55.0)
40e50 50e60 60e70 70
235 (7.3) 727 (15.2) 599 (27.6) 413 (37.5)
2968 (92.7) 4043 (84.8) 1568 (72.4) 689 (62.5)
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Fig. 4. Platelet count in different age groups stratified by metabolic syndrome in (A) men and (B) women.
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+ MODELand whether they took medication to control these diseases
was not documented, either. Fifth, the gold standard for the
diagnosis of fatty liver is liver biopsy. However, the inva-
siveness of that procedure means that it is not feasible for the
general population. The lack of biopsy results also prevented
us from further analyzing the influence of fibrosis severity. In
the present study, the diagnosis of fatty liver was made by
ultrasonography and defined by at least two of three abnormal
findings: diffusely increased echogenic liver greater than
kidney or spleen, vascular blurring, and deep attenuation of
ultrasound signal with a sensitivity of 89% and specificity of
93%.39,40
In conclusion, the present study indicated a significant
correlation between PC and MS, and the association existed
independent of gender, age, and status of fatty liver. PC may
act as a surrogate marker for MS, and physicians should be
concerned with the presence of MS among patients with high
PC.Please cite this article in press as: Fang K-C, et al., Higher platelet counts are assoc
the Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.07Acknowledgments
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